Nafamostat
- Generic Name
- Nafamostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H17N5O2
- CAS Number
- 81525-10-2
- Unique Ingredient Identifier
- Y25LQ0H97D
- Background
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal ...
- Indication
Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement therapy and extra corporeal membrane oxygenation.
- Associated Conditions
- -
- Associated Therapies
- -
A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06676085
- Locations
- 🇨🇳
Bing Sun, Beijing, Beijing, China
Effect of Nafamostat on Postreperfusion Syndrome (PRS)
- Conditions
- Interventions
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2010-05-11
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT01001403
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.